To provide evidence-based recommendations for the management of phyllodes tumours (PT) in the breast, addressing variations in clinical practice and improving patient care.
Key Findings:
Phyllodes tumours account for about 0.5% of all breast tumours, with varying classifications: benign (50-70%), borderline (12-26%), and malignant (20-30%).
Management of PT varies significantly both internationally and within the UK, often leading to overtreatment of benign lesions.
Specialist sarcoma services improve patient outcomes, reducing the need for multiple operations.
Interpretation:
The guidelines aim to standardize the management of PT, ensuring that patients receive appropriate treatment based on tumour classification and clinical context.
Limitations:
Economic evaluation was not conducted, limiting insights into cost-effectiveness.
Variability in clinical practice may still exist despite guidelines.
Conclusion:
These guidelines serve as a resource for multidisciplinary teams to enhance the management of phyllodes tumours, promoting best practices and improving patient outcomes.
by Mai K Bishr, Alex Humphreys, Mahbubl Ahmed, Karina Cox, Adam Hughes, Jen Isherwood, Sarah E Pinder, Dionysios D Remoundos, Elinor Sawyer, Muhammad S Tamimy, Lisa Whisker
The rising incidence and mortality of early-onset colorectal cancer (EOCRC), defined as disease occurring in patients younger than 50, has emerged as a clinically significant trend with implications for screening, diagnosis, and survivorship.
